Antenatal screening for down syndrome: A quantitative demonstration of the improvements over the past 20 years

Journal of Health Services Research and Policy

Volumn 18, Issue 4, 2013, Pages 195-201

  Renshaw, Richard ^a   Ellis, Katrina ^a   Jacobs, Patricia ^b   Morris, Joan ^c  

^a SALISBURY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Amniocentesis; Chorionic villus sampling; Prenatal diagnosis; Screening

Indexed keywords

ADULT; AMNIOCENTESIS; ARTICLE; CHORION VILLUS SAMPLING; CONTROLLED STUDY; DOWN SYNDROME; EDWARDS SYNDROME; FEMALE; FETUS DEATH; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; TRISOMY 13; UNITED KINGDOM;

AMNIOCENTESIS; CHORIONIC VILLUS SAMPLING; PRENATAL DIAGNOSIS; SCREENING;

ADULT; AMNIOCENTESIS; CHORIONIC VILLI SAMPLING; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 13; DATABASES, FACTUAL; DOWN SYNDROME; ENGLAND; FEMALE; HUMANS; PREGNANCY; PRENATAL DIAGNOSIS; QUALITY IMPROVEMENT; TRISOMY;

EID: 84890248561     PISSN: 13558196     EISSN: None     Source Type: Journal    
DOI: 10.1177/1355819613482116     Document Type: Article

References (14)

1. Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003; 10: 56-104.
2. Nicolaides KH, Azar G, Byrne D, et al. Fetal nuchal translucency: ultrasound screening for chromosomal defects in the first trimester of pregnancy. Br Med J 1992; 304: 867-869.
3. De Biasio P, Siccardi M, Volpe G, et al. First-trimester screening for Down syndrome using nuchal translucency measurement with free beta hCG and PPAP-A between 10 and 13 weeks of pregnancy-the combined test. Prenat Diag 1999; 19: 360-363.
4. Wald NJ, Watt HC and Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999; 341: 461-467.
5. Tabor A, Vestergaard HF and Lidegaard O. Fetal loss rate after chorionic villus sampling and amniocentesis: an 11- year national registry study. Ultrasound Obstet Gynaecol 2009; 34: 19-24.
6. Mujezinovic F and Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villus sampling. A systematic review. Obstet Gynecol 2007; 110: 687-694.
7. Tabor A, Madsen M, Obel E, et al. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986; 1: 1287-1293.
8. Wald NJ, Bestwick JP, Huttly WJ, et al. Validation plots in antenatal screening for Down's syndrome. J Med Screen 2006; 13: 166-171.
9. Morris JK and Savva GM. The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18. Am J Med Genet A 2008; 146A: 827-832.
10. Savva GM, Morris JK, Mutton DE, et al. Maternal agespecific fetal loss rates in Down syndrome pregnancies. Prenat Diagn 2006; 26: 499-504.
11. Morris JK, Mutton DE and Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 2002; 9: 2-6.
12. Savva GM, Morris JK and Walker K. The maternal age specific prevalence of trisomy 13 and trisomy 18. Prenat Diagn 2010; 30: 57-64.
13. Ehrich M, Deciu C, Zwiefelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011; 204: 205.e1-205.e11.
14. Chiu RWK, Akolekar R, Zheng YWL, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: a large scale validity study. Br Med J 2001; 342: c7401.